| Title |
Clinical utility of targeted treatments in the management of epithelial ovarian cancer
|
|---|---|
| Published in |
Biologics: Targets & Therapy, July 2012
|
| DOI | 10.2147/btt.s29356 |
| Pubmed ID | |
| Authors |
Cheryl Twu, Ernest S Han |
| Abstract |
Epithelial ovarian cancer is typically found in its advanced stages, where a combination of surgical debulking and platinum/taxane-based chemotherapy is recommended. Although over 70%-80% of patients achieve remission, a significant proportion develop recurrence of their disease. Additional cytotoxic chemotherapy, as well as surgery, is typically used to manage disease recurrence. Therapies that target specific pathways in cancer cells are rapidly developing in the laboratory and are increasingly being studied in patients with ovarian cancer. We review the current status of novel therapies in the management of epithelial ovarian cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 7 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 43% |
| Student > Doctoral Student | 1 | 14% |
| Other | 1 | 14% |
| Professor | 1 | 14% |
| Student > Master | 1 | 14% |
| Other | 0 | 0% |
| Readers by discipline | Count | As % |
|---|---|---|
| Physics and Astronomy | 2 | 29% |
| Biochemistry, Genetics and Molecular Biology | 1 | 14% |
| Economics, Econometrics and Finance | 1 | 14% |
| Agricultural and Biological Sciences | 1 | 14% |
| Psychology | 1 | 14% |
| Other | 1 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2012.
All research outputs
#17,408,360
of 25,540,105 outputs
Outputs from Biologics: Targets & Therapy
#192
of 285 outputs
Outputs of similar age
#116,677
of 177,017 outputs
Outputs of similar age from Biologics: Targets & Therapy
#12
of 13 outputs
Altmetric has tracked 25,540,105 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,017 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.